|
1
|
Li S, Young KH and Medeiros LJ: Diffuse
large B-cell lymphoma. Pathology. 50:74–87. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miyazaki K: Treatment of diffuse large
B-cell lymphoma. J Clin Exp Hematop. 56:79–88. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kubuschok B, Held G and Pfreundschuh M:
Management of diffuse large B-cell lymphoma (DLBCL). Cancer Treat
Res. 165:271–288. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cardinale D, Colombo A, Bacchiani G,
Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N,
Curigliano G, et al: Early detection of anthracycline
cardiotoxicity and improvement with heart failure therapy.
Circulation. 131:1981–1988. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Linschoten M, Teske AJ, Baas AF, Vink A,
Dooijes D, Baars HF and Asselbergs FW: Truncating Titin (TTN)
variants in chemotherapy-induced cardiomyopathy. J Card Fail.
23:476–479. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ewer MS and Ewer SM: Cardiotoxicity of
anticancer treatments. J Nat Rev Cardiol. 12:547–558. 2015.
View Article : Google Scholar
|
|
7
|
Laursen AH, Thune JJ, Hutchings M, Hasbak
P, Kjaer A, Elming MB and Ripa RS: 123I-MIBG imaging for
detection of anthracycline-induced cardiomyopathy. Clin Physiol
Funct Imaging. 38:176–185. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mcmurray JJ, Adamopoulos S, Anker SD,
Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C,
Gomez-Sanchez MA, et al: ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure 2012: The Task Force
for the diagnosis and treatment of acute and chronic heart failure
2012 of the European Society of Cardiology. Developed in
collaboration with the Heart Failure Association (HFA) of the ESC.
Eur J Heart Fail. 14:803–869. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dutta T, Spevack DM and Aronow WS: The
left ventricular ejection fraction: New insights into an old
parameter. Hosp Pract (1995). 47:221–230. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ong G, Brezden-Masley C, Dhir V, Deva DP,
Chan KKW, Chow CM, Thavendiranathan D, Haq R, Barfett JJ, Petrella
TM, et al: Myocardial strain imaging by cardiac magnetic resonance
for detection of subclinical myocardial dysfunction in breast
cancer patients receiving trastuzumab and chemotherapy. Int J
Cardiol. 261:228–233. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Virani SA, Dent S, Brezden-Masley C,
Clarke B, Davis MK, Jassal DS, Johnson C, Lemieux J, Paterson I,
Sebag IA, et al: Canadian cardiovascular society guidelines for
evaluation and management of cardiovascular complications of cancer
therapy. Can J Cardiol. 32:831–841. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zamorano JL, Lancellotti P, Muñoz DR,
Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY,
Lyon AR, et al: 2016 ESC Position Paper on cancer treatments and
cardiovascular toxicity developed under the auspices of the ESC
Committee for Practice Guidelines. Kardiol Pol. 74:1193–1233.
2016.(In Polish). View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seraphim A, Westwood M, Bhuva AN, Crake T,
Moon JC, Menezes LJ, Lloyd G, Ghosh AK, Slater S, Oakervee H and
Manisty CH: Advanced imaging modalities to monitor for
cardiotoxicity. Curr Treat Options Oncol. 20:732019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Markman TM, Ruble K, Loeb D, Chen A, Zhang
Y, Beasley GS, Thompson WR and Nazarian S: Electrophysiological
effects of anthracyclines in adult survivors of pediatric
malignancy. Pediatric Blood Cancer. 642017.doi: 10.1002/pbc.26556.
PubMed/NCBI
|
|
15
|
Yu AF, Manrique C, Pun S, Liu JE, Mara E,
Fleisher M, Patil S, Jones LW, Steingart RM, Hudis CA and Dang CT:
Cardiac safety of paclitaxel plus trastuzumab and pertuzumab in
patients with HER2-positive metastatic breast cancer. Oncologist.
21:418–424. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Soufer A, Liu C, Henry ML and Baldassarre
LA: Nuclear cardiology in the context of multimodality imaging to
detect cardiac toxicity from cancer therapeutics: Established and
emerging methods. J Nucl Cardiol. 27:1210–1224. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mahabadi AA and Rischpler C:
Cardiovascular imaging in cardio-oncology. J Thorac Dis. 10 (Suppl
35):S4351–S4366. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gayed IW, Liu HH, Yusuf SW, Komaki R, Wei
X, Wang X, Chang JY, Swafford J, Broemeling L and Liao Z: The
prevalence of myocardial ischemia after concurrent chemoradiation
therapy as detected by gated myocardial perfusion imaging in
patients with esophageal cancer. J Nucl Med. 47:1756–1762.
2006.PubMed/NCBI
|
|
19
|
Zellars R, Bravo PE, Tryggestad E, Hopfer
K, Myers L, Tahari A, Asrari F, Ziessman H and Garrett-Mayer E:
SPECT analysis of cardiac perfusion changes after
whole-breast/chest wall radiation therapy with or without active
breathing coordinator: Results of a randomized phase 3 trial. Int J
Radiat Oncol Biol Phys. 88:778–785. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Germano G, Kavanagh PB, Slomka PJ, Van
Kriekinge SD, Pollard G and Berman DS: Quantitation in gated
perfusion SPECT imaging: The Cedars-Sinai approach. J Nucl Cardiol.
14:433–454. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
King JF and Lam JT: A practical approach
to diagnosis of B-cell lymphomas with diffuse large cell
morphology. Arch Pathol Lab Med. 144:160–167. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sabattini E, Bacci F, Sagramoso C and
Pileri SA: WHO classification of tumours of haematopoietic and
lymphoid tissues in 2008: An overview. Pathologica. 102:83–87.
2010.PubMed/NCBI
|
|
23
|
Rosenberg SA: Validity of the Ann Arbor
staging classification for the non-Hodgkin's lymphomas. J Cancer
Treat Rep. 61:1023–1027. 1977.
|
|
24
|
Perez EA, Suman VJ, Davidson NE, Sledge
GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle
JN, et al: Cardiac safety analysis of doxorubicin and
cyclophosphamide followed by paclitaxel with or without trastuzumab
in the North Central Cancer Treatment Group N9831 adjuvant breast
cancer trial. J Clin Oncol. 26:1231–1238. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goel S, Liu J, Guo H, Barry W, Bell R,
Murray B, Lynch J, Bastick P, Chantrill L, Kiely BE, et al: Decline
in left ventricular ejection fraction following anthracyclines
predicts trastuzumab cardiotoxicity. JACC. Heart Fail. 7:795–804.
2019.
|
|
26
|
Ho E, Brown A, Barrett P, Morgan RB, King
G, Kennedy MJ and Murphy RT: Subclinical anthracycline- and
trastuzumab-induced cardiotoxicity in the long-term follow-up of
asymptomatic breast cancer survivors: A speckle tracking
echocardiographic study. Heart. 96:701–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu W, Li SN, Chan GC, Ha SY, Wong SJ and
Cheung YF: Transmural strain and rotation gradient in survivors of
childhood cancers. Eur Heart J Cardiovasc Imaging. 14:175–182.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Armstrong IS, Arumugam P, James JM, Tonge
CM and Lawson RS: Reduced-count myocardial perfusion SPECT with
resolution recovery. Nucl Med Commun. 33:121–129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cerqueira MD, Weissman NJ, Dilsizian V,
Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T and
Verani MS; American Heart Association Writing Group on Myocardial
Segmentation and Registration for Cardiac Imaging, : Standardized
myocardial segmentation and nomenclature for tomographic imaging of
the heart. A statement for healthcare professionals from the
cardiac imaging committee of the council on clinical cardiology of
the american heart association. J Nucl Cardiol. 9:240–245. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McGowan JV, Chung R, Maulik A, Piotrowska
I, Walker JM and Yellon DM: Anthracycline chemotherapy and
cardiotoxicity. Cardiovasc Drugs Ther. 31:63–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ferraro MP, Gimeno-Vazquez E, Subirana I,
Gómez M, Díaz J, Sánchez-González B, García-Pallarols F, Martínez
L, Ble M, Molina L, et al: Anthracycline-induced cardiotoxicity in
diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score
for risk stratification. Eur J Haematol. 102:509–515.
2019.PubMed/NCBI
|
|
32
|
Zelenetz AD, Gordon LI, Abramson JS,
Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B,
Fayad LE, et al: NCCN guidelines insights: B-cell lymphomas,
version 3.2019. J Natl Compr Canc Netw. 17:650–661. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thieblemont C, Bernard S, Meignan M and
Molina T: Optimizing initial therapy in DLBCL. Best Pract Res Clin
Haematol. 31:199–208. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bansal N, Amdani S, Lipshultz ER and
Lipshultz SE: Chemotherapy-induced cardiotoxicity in children.
Expert Opin Drug Metab Toxicol. 13:817–832. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Veronese P, Hachul DT, Scanavacca MI,
Hajjar LA, Wu TC, Sacilotto L, Veronese C and Darrieux FCDC:
Effects of anthracycline, cyclophosphamide and taxane chemotherapy
on QTc measurements in patients with breast cancer. PLoS One.
13:e01967632018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Porta-Sanchez A, Gilbert C, Spears D, Amir
E, Chan J, Nanthakumar K and Thavendiranathan P: Incidence,
diagnosis, and management of qt prolongation induced by cancer
therapies: A systematic review. J Am Heart Assoc. 6:e0077242017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Heemskerk CPM, Pereboom M, van Stralen K,
Berger FA, van den Bemt PMLA, Kuijper AFM, van der Hoeven RTM,
Mantel-Teeuwisse AK and Becker ML: Risk factors for QTc interval
prolongation. Eur J Clin Pharmacol. 74:183–191. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Puppe J, van Ooyen D, Neise J, Thangarajah
F, Eichler C, Krämer S, Pfister R, Mallmann P, Wirtz M and Michels
G: Evaluation of QTc Interval prolongation in breast cancer
patients after treatment with epirubicin, cyclophosphamide, and
docetaxel and the influence of interobserver variation. Breast Care
(Basel). 12:40–44. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Etchegoyen CV, Keller GA, Mrad S, Cheng S
and Di Girolamo G: Drug-induced QT interval prolongation in the
intensive care unit. Curr Clin Pharmacol. 12:210–222. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Renu K, Abilash VG, Tirupathi PB and
Arunachalam S: Molecular mechanism of Doxorubicin-induced
cardiomyopathy-An update. Eur J Pharmacol. 818:241–253. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Henninger C and Fritz G: Statins in
Anthracycline-induced cardiotoxicity: Rac and Rho, and the
heartbreakers. Cell Death Dis. 8:e25642017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hahn VS, Lenihan DJ and Ky B: Cancer
Therapy-induced cardiotoxicity: Basic mechanisms and potential
cardioprotective therapies. J Am Heart Assoc. 3:e0006652014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rochette L, Guenancia C, Gudjoncik A,
Hachet O, Zeller M, Cottin Y and Vergely C:
Anthracyclines/trastuzumab: New aspects of cardiotoxicity and
molecular mechanisms. Trends Pharmacol Sci. 36:326–348. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mukai M, Komori K and Oka T: Mechanism and
management of cancer Chemotherapy-induced atherosclerosis. J
Atheroscler Thromb. 25:994–1002. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yin J, Guo J, Zhang Q, Cui L, Zhang L,
Zhang T, Zhao J, Li J, Middleton A, Carmichael PL and Peng S:
Doxorubicin-induced mitophagy and mitochondrial damage is
associated with dysregulation of the PINK1/parkin pathway. Toxicol
In Vitro. 51:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Koleini N and Kardami E: Autophagy and
mitophagy in the context of Doxorubicin-induced cardiotoxicity.
Oncotarget. 8:46663–46680. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ichikawa Y, Ghanefar M, Bayeva M, Wu R,
Khechaduri A, Naga Prasad SV, Mutharasan RK, Naik TJ and Ardehali
H: Cardiotoxicity of doxorubicin is mediated through mitochondrial
iron accumulation. J Clin Invest. 124:617–630. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Beller GA and Watson DD: Physiological
basis of myocardial perfusion imaging with the technetium 99m
agents. Semin Nucl Med. 21:173–181. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li J, Lu J and Zhou Y:
Mitochondrial-targeted molecular imaging in cardiac disease. Biomed
Res Int. 2017:52468532017.PubMed/NCBI
|
|
50
|
Bartholoma MD, Zhang S, Akurathi V, Pacak
CA, Dunning P, Fahey FH, Cowan DB, Treves ST and Packard AB:
(18)F-labeled rhodamines as potential myocardial perfusion agents:
Comparison of pharmacokinetic properties of several rhodamines.
Nucl Med Biol. 42:796–803. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang L, Liu Z, Hu KY, Tian QB, Wei LG,
Zhao Z, Shen HR and Hu J: Early myocardial damage assessment in
dystrophinopathies using (99)Tc(m)-MIBI gated myocardial perfusion
imaging. Ther Clin Risk Manag. 11:1819–1827. 2015.PubMed/NCBI
|
|
52
|
Arruda-Olson AM, Roger VL, Jaffe AS, Hodge
DO, Gibbons RJ and Miller TD: Troponin T levels and infarct size by
SPECT myocardial perfusion imaging. JACC Cardiovasc Imaging.
4:523–533. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sood N, Al Badarin F, Parker M, Pullatt R,
Jacobson AF, Bateman TM and Heller GV: Resting perfusion MPI-SPECT
combined with cardiac 123I-mIBG sympathetic innervation imaging
improves prediction of arrhythmic events in Non-ischemic
cardiomyopathy Patients: Sub-study from the ADMIRE-HF trial. J Nucl
Cardiol. 20:813–820. 2013. View Article : Google Scholar : PubMed/NCBI
|
